A Phase 2 interventional study of Vorinostat in Lymphoma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing vorinostat in Lymphoma — none open to participants now, 1 under way, 1 of them phase 3. Vorinostat · Lymphoma.
Among the 20 studies testing vorinostat in Lymphoma, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2009, is one of 5 in phase 2, and was the 10th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →None of the 20 studies testing vorinostat in Lymphoma is open now. The open studies under Lymphoma, anywhere →
Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 20 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 2
First in 2000; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is above the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 17 across the 19 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
17 studies in Lymphoma by Merck & Co., Inc: 2 open now, 4 under way, none of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 17 studies in Lymphoma by Merck & Co., Inc, this one is the 9th largest by enrollment, is one of 2 that started in 2009, is one of 3 in phase 2, and was the 9th registered.
Merck & Co., Inc’s Lymphoma studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing vorinostat in Lymphoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 17 in Lymphoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of vorinostat (MK-0683) in participants with relapsed and/or refractory follicular lymphoma. The exploratory purpose of this study is to evaluate efficacy of MK-0683 in participants with relapsed/refractory non-FL indolent B-NHL or relapsed/refractory MCL. The primary hypothesis is that MK-0683 will show efficacy in relapsed/refractory FL patients as measured by the Overall Response Rate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant has an histopathologically confirmed follicular lymphoma (FL), or other indolent B-cell non-Hodgkin's lymphoma (B-NHL) or mantle cell lymphoma (MCL)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with relapsed/refractory FL received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol.
Drug: Vorinostat
Participants with indolent non-follicular lymphoma (FL) B-cell non-Hodgkin's lymphoma (B-NHL), or with mantle cell Lymphoma (MCL) received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol.
Drug: Vorinostat
Participants with disease other than relapsed/refractory follicular lymphoma (FL), non-FL B-cell non-Hodgkin's lymphoma (B-NHL), or mantle cell Lymphoma (MCL), as assessed by the Independent Central Pathological Committee, received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol. This group was created to include participants who enrolled, but whose later diagnoses by the Independent Central Pathological Committee excluded them from analysis in the FL and non-FL B-NHL/MCL groups because they had different disease than those prespecified in the protocol.
Drug: Vorinostat
Two 100 mg oral capsules of vorinostat, twice daily (400 mg/day), on Days 1 through 14 of each 21 day cycle
Also known as: MK-0683, Zolinza
Objective Response Rate (ORR)
ORR was defined as the percentage of participants who had a Complete Response (CR: Normal liver/spleen physical exam, all lymph nodes and nodal masses are normal, and there is no bone marrow involvement), a Complete Response/unconfirmed (CRu: Normal liver/spleen physical exam, plus at least a 75% decrease in the sum of the products of the greatest diameters of nodal masses if any are greater than 1.5 cm in their greatest diameter, normal or indeterminate bone marrow involvement), or a Partial Response (PR: Either normal physical exam, lymph nodes, and lymph node masses plus positive bone marrow involvement; OR normal physical exam or decrease in liver/spleen size plus at least a 50% decrease in the diameters of lymph nodes and nodal masses) as assessed using the international working group Non-Hodgkin's lymphoma standardized response criteria described by Cheson, BD in 1999. The percentage of participants who experienced a CR, CRu, or PR is presented.
Time frame: Up to 650 days
Number of Participants Who Experienced an Adverse Event (AE)
An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who experienced an AE was presented.
Time frame: Up to approximately 29 months
Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event (AE)
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued from study drug due to an adverse event was reported.
Time frame: Up to 536 days
Time to Treatment Failure for Relapsed/Refractory FL
Time to Treatment Failure is defined as the time from allocation until the date of any treatment failure, including documented disease progression, or discontinuation of the study medication for any reason. Data was censored on the efficacy data cutoff date of 25 February, 2011.
Time frame: Up to 650 days
Time to Response for Relapsed/Refractory FL
Time to Response is defined as the time from allocation until the time of an initial response. Data was censored on the efficacy data cutoff date of 25 February, 2011.
Time frame: Up to 650 days
| Milestone | Follicular Lymphoma (FL) | Indolent Non-FL B-NHL or MCL | Other Disease |
|---|---|---|---|
| Started | 39 | 11 | 6 |
| Completed | 5 | 2 | 0 |
| Not completed | 34 | 9 | 6 |
| Withdrew: Adverse event | 8 | 1 | 2 |
| Withdrew: Physician decision | 2 | 0 | 0 |
| Withdrew: Progressive disease | 20 | 8 | 3 |
| Withdrew: Withdrawal by subject | 4 | 0 | 1 |
ORR was defined as the percentage of participants who had a Complete Response (CR: Normal liver/spleen physical exam, all lymph nodes and nodal masses are normal, and there is no bone marrow involvement), a Complete Response/unconfirmed (CRu: Normal liver/spleen physical exam, plus at least a 75% decrease in the sum of the products of the greatest diameters of nodal masses if any are greater than 1.5 cm in their greatest diameter, normal or indeterminate bone marrow involvement), or a Partial Response (PR: Either normal physical exam, lymph nodes, and lymph node masses plus positive bone marrow involvement; OR normal physical exam or decrease in liver/spleen size plus at least a 50% decrease in the diameters of lymph nodes and nodal masses) as assessed using the international working group Non-Hodgkin's lymphoma standardized response criteria described by Cheson, BD in 1999. The percentage of participants who experienced a CR, CRu, or PR is presented.
| Percentage of participants | Follicular Lymphoma (FL) | Indolent Non-FL B-NHL or MCL | Other Disease |
|---|---|---|---|
| Objective Response Rate (ORR) | 48.7 (32.4 to 65.2) | 27.3 (6.0 to 61.0) | — |
An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who experienced an AE was presented.
| Participants | Follicular Lymphoma (FL) | Indolent Non-FL B-NHL or MCL | Other Disease |
|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 39 | 11 | 6 |
Time to Treatment Failure is defined as the time from allocation until the date of any treatment failure, including documented disease progression, or discontinuation of the study medication for any reason. Data was censored on the efficacy data cutoff date of 25 February, 2011.
| Days | Follicular Lymphoma (FL) | Indolent Non-FL B-NHL or MCL | Other Disease |
|---|---|---|---|
| Time to Treatment Failure for Relapsed/Refractory FL | 323 (60 to NA) | — | — |
Time to Response is defined as the time from allocation until the time of an initial response. Data was censored on the efficacy data cutoff date of 25 February, 2011.
| Days | Follicular Lymphoma (FL) | Indolent Non-FL B-NHL or MCL | Other Disease |
|---|---|---|---|
| Time to Response for Relapsed/Refractory FL | NA (NA to NA) | — | — |
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued from study drug due to an adverse event was reported.
| Participants | Follicular Lymphoma (FL) | Indolent Non-FL B-NHL or MCL | Other Disease |
|---|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event (AE) | 6 | 1 | 2 |
Collected over Up to approximately 65 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Follicular Lymphoma (FL) | 9/39 (23.1%) | 15/39 (38.5%) | 39/39 (100%) |
| Indolent Non-FL B-NHL or MCL | 4/11 (36.4%) | 4/11 (36.4%) | 11/11 (100%) |
| Other Disease | 3/6 (50%) | 2/6 (33.3%) | 6/6 (100%) |
| Event | Follicular Lymphoma (FL) | Indolent Non-FL B-NHL or MCL | Other Disease |
|---|---|---|---|
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/39 | 0/11 | 1/6 |
| VIth nerve paralysisNervous system disorders | 0/39 | 0/11 | 1/6 |
| NeutropeniaBlood and lymphatic system disorders | 0/39 | 1/11 | 0/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/39 | 1/11 | 0/6 |
| PneumoniaInfections and infestations | 1/39 | 1/11 | 0/6 |
| HaemothoraxRespiratory, thoracic and mediastinal disorders | 0/39 | 1/11 | 0/6 |
| InfluenzaInfections and infestations | 0/39 | 1/11 | 0/6 |
| Anogenital wartsNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/39 | 1/11 | 0/6 |
| Renal impairmentRenal and urinary disorders | 0/39 | 1/11 | 0/6 |
| Decreased appetiteMetabolism and nutrition disorders | 2/39 | 0/11 | 0/6 |
| Event | Follicular Lymphoma (FL) | Indolent Non-FL B-NHL or MCL | Other Disease |
|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 37/39 | 10/11 | 5/6 |
| DiarrhoeaGastrointestinal disorders | 28/39 | 9/11 | 5/6 |
| NeutropeniaBlood and lymphatic system disorders | 29/39 | 7/11 | 2/6 |
| LeukopeniaBlood and lymphatic system disorders | 20/39 | 8/11 | 3/6 |
| Decreased appetiteMetabolism and nutrition disorders | 27/39 | 6/11 | 3/6 |
| LymphopeniaBlood and lymphatic system disorders | 13/39 | 7/11 | 0/6 |
| NauseaGastrointestinal disorders | 24/39 | 7/11 | 3/6 |
| FatigueGeneral disorders | 22/39 | 5/11 | 2/6 |
| DysgeusiaNervous system disorders | 14/39 | 3/11 | 3/6 |
| NasopharyngitisInfections and infestations | 19/39 | 4/11 | 1/6 |
| Age, Continuous(Years) | Follicular Lymphoma (FL) | Indolent Non-FL B-NHL or MCL | Other Disease | Total |
|---|---|---|---|---|
| Mean | 57.4 ± 10.4 | 62.9 ± 9.7 | 56.3 ± 10.5 | 58.4 ± 10.4 |
| Sex: Female, Male(Participants) | Follicular Lymphoma (FL) | Indolent Non-FL B-NHL or MCL | Other Disease | Total |
|---|---|---|---|---|
| Female | 24 | 4 | 2 | 30 |
| Male | 15 | 7 | 4 | 26 |
| Ethnicity (NIH/OMB)(Participants) | Follicular Lymphoma (FL) | Indolent Non-FL B-NHL or MCL | Other Disease | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 39 | 11 | 6 | 56 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Follicular Lymphoma (FL) | Indolent Non-FL B-NHL or MCL | Other Disease | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 39 | 11 | 6 | 56 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Apr 2009 to primary completion in Sep 2011, 28 months.
Results were first posted in Oct 2020, 9 years 1 month after primary completion.
Of 56 industry-sponsored phase 2 interventional studies under Lymphoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 28 months is below that.
Counting every sponsor, half of 293 studies reached it within 61 months; a quarter within 36 and three quarters within 105.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorinostat